Bilateral renal metastases from papillary thyroid carcinoma on post ¹³¹I treatment scan: Flip-flop sign, radioiodine SPET, ¹⁸F-FDG PET, CECT and histopathological correlation

To the Editor: Papillary thyroid carcinoma is known to metastasize preferably to lymph nodes; however 10% of cases may show distant metastases, mainly to lungs and bones [1]. Rare cases of metastases to kidneys have been reported in the literature, which occurred mostly after a considerable period of latency post thyroidectomy and radio-iodine treatment [2, 3].

Herein, we report a case of a 56 years old male patient who was diagnosed with papillary carcinoma of the thyroid with lymph node metastases. Following total thyroid ectomy he received 1.85GBq of iodine-131 (¹³¹I) for thyroid remnant ablation.

The intensity of ¹⁸F-FDG uptake in these foci demonstrated a flip-flop pattern with respect to the uptake of ¹³¹I (clarified further on post-furosemide delayed, limited scan) among the renal metastases. An additional small focus of ¹⁸F-FDG uptake was seen in the upper pole of the left kidney (this was not noted on the post ¹³¹I treatment planar or SPET images). No other abnormal ¹⁸F-FDG uptake was noted on the whole body PET scan (Fig. 1-5).




Figure 1. Post radio-iodine-131 treatment scan, undertaken while discharging the patient from the ward at exposure rate of <3mR/h at 1m distance revealed intense uptake in the thyroid bed, faint uptake in upper mediastinum along with, intense, focal uptake in right renal region that was prominent on posterior view of ¹³¹I-whole body scan.

The case illustrates the value of post ¹³¹I treatment SPET imaging by the fact that at times it can offer higher accuracy in discerning the nature of tracer uptake with respect to conventional planar whole body imaging [4]. Especially helpful was to the ¹⁸F-FDG-radioiodine "flip-flop" in the presented case amongst the metastatic lesions in the two kidneys and the extent of ¹³¹I concentrating/non-concentrating disease. In conclusion, our findings help in delineating and understanding tumor biology and provide critical information in thyroid cancer management.

The authors have no conflicts of interest.



Figures 2 and 3. ¹³¹I-SPET study (**Fig. 2**) further clarified these foci in both kidneys. ¹⁸F-FDG-PET scan (**Fig. 3**) done on a separate day revealed abnormal foci of ¹⁸F-FDG uptake in the lower poles of both kidneys, corresponding to the foci seen on post treatment ¹³¹I-SPET. In the ¹⁸F-FDG-PET image, the foci can be well visualized and appreciated in the coronal slice (arrows) while in the MIP image the relatively intense overlapping gut uptake obscures the pattern of uptake in the foci.




Figure 4. A limited-region contrast enhanced CT scan (CECT) of abdomen after a few days demonstrated 5.5X5cm sized exophytic, heterogeneously enhancing soft tissue mass in the lower pole of left kidney (red arrow in the lower panel). Similar 1.4X1.3cm and 1.5X1.3cm sized mass lesions were seen in the lower pole of right kidney (red arrow in the lower panel) on the left side of the image) and in the upper pole of left kidney (red arrow in the upper panel), respectively, corroborating the PET lesions.




Figure 5a and b. A CT guided FNAC from the lesions was consistent with the diagnosis of metastases from papillary thyroid carcinoma 5a: Aspirate revealing few sheets and clusters with vascular cores. 5b: Higher power view demonstrates pale nuclear chromatin and intranuclear inclusions (arrows).

Bibliography

- 1. Schlumberger M, Pacini F. *Thyroid tumors*. Editions Nucleon, Paris, 2006: 42.
- Matei DV, Verweij F. Late solitary thyroid carcinoma metastasis to the kidney: a case report; *Anticancer research* 2003; 23: 561-4.
- 3 Insabato L, Di Vizio D, De Rosa G et al. Renal metastasis from thyroid carcinoma 35 years after detection of primary tumor. *Tumori* 2003; 89: 99-101.
- Kohlfuerst S, Igerc I, Lobnig M et al. Posttherapeutic ¹³¹I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. *Eur J Nucl Med Mol Imaging* 2009; 36: 886-93.

Chaitanya Borde¹ MBBS DRM, Sandip Basu¹ MBBS (Hons) DRM DNB MNAMS, Purushottam Kand¹ MBBS DRM DNB MNAMS, Supreeta Arya² MBBS MD, Tanuja Shet³ MBBS MD

1. Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, Bombay 400 012, 2. Department of Radiology and 3. Department of Pathology, Tata Memorial Hospital, Jerbai Wadia Road, Parel, Bombay 400 012

Dr. Sandip Basu, MBBS

Radiation Medicine Centre (BARC), Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, Bombay 400 012 Email:drsanb@yahoo.com, Fax: 24157098

Hell J Nucl Med 2011:14(1): 72-73

Published on line: 5 March 2011